Key clinical point: Patients with early-stage triple-negative breast cancer (TNBC) should receive adjuvant chemotherapy without unnecessary delays after primary surgery because prognosis may worsen if treatment is postponed beyond 6 weeks.
Major finding: Patients who received adjuvant systemic therapy within 22-28 days after surgery reported the most favorable overall survival (OS) outcomes (median OS 10.2 years), with the OS decreasing in the groups that received adjuvant systemic therapy during 29-35 days, 36-42 days, and >6 weeks after surgery (8.3 years, 7.8 years, and 6.9 years, respectively).
Study details: Findings are from a retrospective cohort study that included 245 patients with early TNBC who received adjuvant chemotherapy after primary surgery .
Disclosures: The open access funding for this study was enabled and organized by Projekt DEAL. Some authors declared receiving honoraria or travel reimbursements from or serving as consultants or board members for various sources.
Source: Hatzipanagiotou ME, Pigerl M, Gerken M, et al. Clinical impact of delaying initiation of adjuvant chemotherapy in patients with early triple negative breast cancer. Breast Cancer Res Treat. 2024 (Jan 19). doi: 10.1007/s10549-023-07207-4 Source